Loading
A phase 2 trial of Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Betta Pharmaceuticals Co., Ltd., now recruiting.
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI is a phase 2 interventional study registered as NCT07181499 by Betta Pharmaceuticals Co., Ltd., with 28 participants planned, started 2025-09 and due to reach its primary completion in 2028-11. Interventions recorded: Befotertinib and Pemetrexed + Carboplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Non-small-cell lung cancer and the tag pipeline.